Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Testosterone Levels in People Taking Regular Low-Dose Sustained-Release Morphine for Persisting Breathlessness : An Exploratory Study

Ferreira, Diana H. ; Ekstrom, Magnus LU orcid ; Fazekas, Belinda and Currow, David C. (2023) In Journal of Palliative Medicine 26(3). p.402-405
Abstract

Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All... (More)

Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All three had worsening illness at the time of the second assessment. There was no apparent relationship between change in testosterone, morphine dose, and change in breathlessness. Conclusions: Substantial declines in testosterone were uncommon and were not apparently related to changes in morphine dose or breathlessness, but they were possibly related with worsening illness.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
persistent breathlessness, placebo, randomized controlled trial, safety, sustained-release morphine, testosterone
in
Journal of Palliative Medicine
volume
26
issue
3
pages
4 pages
publisher
Mary Ann Liebert, Inc.
external identifiers
  • pmid:36394475
  • scopus:85149415139
ISSN
1096-6218
DOI
10.1089/jpm.2022.0381
language
English
LU publication?
yes
additional info
Publisher Copyright: © Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.
id
8fd256a0-1d9f-4432-b36b-8b5014b1cbd5
date added to LUP
2024-01-12 14:25:12
date last changed
2024-04-13 07:51:49
@article{8fd256a0-1d9f-4432-b36b-8b5014b1cbd5,
  abstract     = {{<p>Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All three had worsening illness at the time of the second assessment. There was no apparent relationship between change in testosterone, morphine dose, and change in breathlessness. Conclusions: Substantial declines in testosterone were uncommon and were not apparently related to changes in morphine dose or breathlessness, but they were possibly related with worsening illness.</p>}},
  author       = {{Ferreira, Diana H. and Ekstrom, Magnus and Fazekas, Belinda and Currow, David C.}},
  issn         = {{1096-6218}},
  keywords     = {{persistent breathlessness; placebo; randomized controlled trial; safety; sustained-release morphine; testosterone}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3}},
  pages        = {{402--405}},
  publisher    = {{Mary Ann Liebert, Inc.}},
  series       = {{Journal of Palliative Medicine}},
  title        = {{Testosterone Levels in People Taking Regular Low-Dose Sustained-Release Morphine for Persisting Breathlessness : An Exploratory Study}},
  url          = {{http://dx.doi.org/10.1089/jpm.2022.0381}},
  doi          = {{10.1089/jpm.2022.0381}},
  volume       = {{26}},
  year         = {{2023}},
}